Compare Diageo plc (DEO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs State Street SPDR S&P Biotech ETF — how do they compare? Diageo plc trades at $86.73 (market cap $47.67B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Diageo plc is far larger — about 4.7× State Street SPDR S&P Biotech ETF's market cap, and Diageo plc pays a 2.3% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DEO | XBI | |
|---|---|---|
Market Cap | $47.67B | $10.11B |
Volume | 893,372 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $102.14 | $169.55 |
52-Week Low | $72.47 | $104.99 |
Typical Hold Time | 66 Days | 38 Days |
Enterprise Value | $68.09B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical signals from moving averages. The company shows strong profitability with 59.47% gross margins and has beaten earnings estimates in the last three quarters. Recent developments include a new CFO appointment and marketing initiatives across key brands. The stock faces headwinds from declining 2026 revenue projections but maintains solid cash flow generation.
DEO presents a mixed outlook with analyst consensus leaning bullish (49% buy ratings) but facing execution risks in its US turnaround. The stock's premium valuation (P/E 27.9) requires sustained earnings growth, while regulatory challenges in India and competitive pressures warrant monitoring. Near-term catalysts include dividend payments and brand revitalization efforts.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
